Cellebrite price target raised to $17 from $13 at BofA

BofA analyst Tomer Zilberman raised the firm’s price target on Cellebrite to $17 from $13 and keeps a Buy rating on the shares. Cellebrite reported better than expected Q2 results, with revenue growth of 24.8% year over year and a 3c beat to EPS estimates, the analyst tells investors in a research note. Q3 and Q4 guidance was above Street expectations across all metrics, reflecting a healthy demand environment, the firm says.